1. Home
  2. ADX vs BEAM Comparison

ADX vs BEAM Comparison

Compare ADX & BEAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Adams Diversified Equity Fund Inc.

ADX

Adams Diversified Equity Fund Inc.

HOLD

Current Price

$23.25

Market Cap

2.8B

Sector

Finance

ML Signal

HOLD

Logo Beam Therapeutics Inc.

BEAM

Beam Therapeutics Inc.

HOLD

Current Price

$30.65

Market Cap

2.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ADX
BEAM
Founded
1840
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.8B
2.8B
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
ADX
BEAM
Price
$23.25
$30.65
Analyst Decision
Buy
Analyst Count
0
14
Target Price
N/A
$46.00
AVG Volume (30 Days)
182.4K
2.0M
Earning Date
01-01-0001
02-24-2026
Dividend Yield
6.68%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$55,701,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$26.52
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$14.94
$13.53
52 Week High
$19.57
$36.44

Technical Indicators

Market Signals
Indicator
ADX
BEAM
Relative Strength Index (RSI) 51.42 52.77
Support Level $23.17 $30.16
Resistance Level $23.69 $35.34
Average True Range (ATR) 0.24 2.67
MACD -0.01 -0.15
Stochastic Oscillator 53.76 37.84

Price Performance

Historical Comparison
ADX
BEAM

About ADX Adams Diversified Equity Fund Inc.

Adams Diversified Equity Fund Inc is a diversified investment company. It is an internally managed closed-end fund whose investment objectives are the preservation of capital, the attainment of reasonable income from investments, and an opportunity for capital appreciation. It invests a majority of its assets in very liquid S&P 500 stocks, and has broad flexibility in the selection of stocks, but maintains a sector neutral approach. The fund has a diversified equity portfolio which consists of securities of companies from energy, consumer staples, information technology, financials, and other sectors.

About BEAM Beam Therapeutics Inc.

Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.

Share on Social Networks: